Cell-Based Defibrotide Potency Assay for Batch Standardization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for assessing the biological activity of defibrotide are inadequate as they do not provide a reliable and accurate measure of potency in a cellular context, leading to variability in batch quality and patient dosing.
Innovation Solution
A cell-based method is developed to assess defibrotide potency by measuring its ability to protect mammalian cells from cytotoxic agents, using defined mammalian cell lines and cytotoxic agents like fludarabine and doxorubicin, with standardized measurement units for effective and safe administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing assays (fibrin plate test, thromboelastographic recording, plasmin method, euglobulin method) are used to evaluate defibrotide biological activity, then the assessment is based on pro-fibrinolytic properties and involves isolated proteins or enzymes, but the method does not provide reliable and accurate potency measurement in a cellular context and leads to variability in batch quality
Solution Approach 1:
The patent introduces mammalian cells as an intermediary system to assess defibrotide potency. Instead of directly measuring pro-fibrinolytic activity on isolated proteins, the method uses cells as a biological sensor that integrates multiple biological activities. The cells are exposed to defibrotide and cytotoxic agents, and cell viability or protection is measured to determine potency, providing a more reliable and accurate assessment that reflects actual biological performance in a cellular context.
Solution Approach 2:
The patent changes the measurement parameter from direct pro-fibrinolytic activity (isolated protein/enzyme level) to cell-based protective effect (cell viability, proliferation, or protection against cytotoxicity). This parameter change enables the assessment to capture the actual biological impact of defibrotide on living systems, thereby improving both measurement precision and batch quality consistency across different manufacturing processes.
2Adaptability or versatility
If defibrotide is extracted from mammalian organs and produced through different manufacturing processes, then the substance can be standardized, but variability in chain length, molecular weight, composition, and degree of sulphation occurs between batches
Solution Approach 1:
The patent implements a feedback mechanism through the cell-based assay that provides quantitative data on defibrotide biological activity. The assay measures cell protection or viability in response to defibrotide treatment, generating a numerical output that can be used to standardize batches. This feedback loop allows manufacturers to adjust and compare different batches based on their actual biological performance, ensuring consistency despite variations in extraction source or manufacturing process.
3Ease of manufacture
If traditional assays are used for quality control during manufacturing, then the process can be monitored, but the methods do not provide consistent dosing guidance for patients across different manufacturing processes and sources
Solution Approach 1:
The patent creates a universal cell-based assay system that serves multiple functions: it provides quality control during manufacturing, enables batch standardization, and establishes a reference for consistent dosing. The same cell-based methodology can be applied across different manufacturing processes and sources, creating a unified standard that ensures both manufacturing quality and clinical dosing consistency. The assay's ability to measure biological activity in a cellular context makes it universally applicable for both quality control and dosing guidance.
Data Source
AI summary
The present invention relates to cell-based methods for determining the biological activity of defibrotide. In particular, the invention provides a method for assessing the potency of defibrotide by assessing the viability of mammalian cells in the presence of at least one cytotoxic agent and one or more concentrations of defibrotide. Such methods are particularly useful for standardizing pharmaceutical compositions comprising defibrotide.